Big data DNA firm Synteka Bio banks US$17.1m in series C round

Synteka Bio, which develops drugs based on big data analysis of DNA, raised US$17.1 million in a series C round. The round was for preferred shareholders to convert their shares into common stock before IPO. Earlier this year, the company selected KB Securities as their book runner for the planned IPO.

The company has been collaborating with CJ Healthcare and JW Pharmaceutical for research and drug discovery.

Leave a Reply

Your email address will not be published. Required fields are marked *